Wyniki wyszukiwania

1

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine

100%

Slomiany B. L., Liu J., Piotrowski J., Czajkowski A., Yotsumoto F., Slomiany A.

Journal of Physiology and Pharmacology

|

1994

|

tom 45

|

nr 1

2

Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease

100%

Sito E., Thor P. J., Maczka M., Lorens K., Konturek S. J., Maj A.

Journal of Physiology and Pharmacology

|

1993

|

tom 44

|

nr 3

3

Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans

86%

Maczka M., Kwiecien N., Obtulowicz W., Konturek S. J., Kaminski K., Oleksy J., Gabryelewicz A., Torres J.

Journal of Physiology and Pharmacology

|

1992

|

tom 43

|

nr 2

This study was designed to assess the gastric secretory effects of ebrotidine, a novel H₂ receptor antagonist, in humans. Three groups (A, В and C) of male subjects with normal gastric mucosa were used. Group A (6 subjects) was used to determine the dose-dependency of gastric inhibitory effect of ebrotidine on basal and pentagastrin- induced maximal acid output. Group В (8 subjects) was employed to examine the duration of the inhibitory effect of ebrotidine on basal and pentagastrin-induced acid secretion. In group C (6 subjects), the 24 h pH-metry was assessed using intraluminal pH-electrode placed in the gastric corpus and connected to a portable recording unit. Single oral dose of ebrotidine (200, 400 or 800 mg) caused a dose- dependent reduction in basal and pentagastrin-induced acid secretion that at a dose of 800 mg amounted to about 89% and 93%, respectively. This inhibition was still observed after 6h and averaged 72% and 50%, respectively. After 12 and 24 h upon the drug intake, both basal and pentagastrin-induced acid secretion returned to the control values. Single oral dose of ebrotidine (800 mg) caused a significant reduction in circadian acidity and resulted in a marked and significant reduction of intragastric acidity for about 6 h upon the administration. This inhibition was accompanied by a transient increase in basal and postprandial gastrin levels. We conclude that ebrotidine is highly effective inhibitor of basal, pentagastrin-induced and circadian gastric acid secretion in humans.

4

Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide

72%

Slomiany B. L., Piotrowski J., Slomiany A.

Journal of Physiology and Pharmacology

|

1999

|

tom 50

|

nr 3

5

Omeprazole fails to suppress up-regulation of gastric mucosal endothelin-converting enzyme-1 by Helicobacter pylori lipopolysaccharide

72%

Slomiany B. L., Piotrowski J., Slomiany A.

Journal of Physiology and Pharmacology

|

2000

|

tom 51

|

nr 3

6

Endothelin-1, interleukin-4 and nitric oxide synthase modulators of gastric mucosal injury by indomethacin: effect of antiulcer agents

58%

Slomiany B. L., Piotrowski J., Slomiany A.

Journal of Physiology and Pharmacology

|

1999

|

tom 50

|

nr 2

7

Susceptibility of Helicobacter pylori to antimicrobial agents : effect of ebrotidine and ranitidine

51%

Piotrowski J., Piotrowski E., Slomiany A., Slomiany B. L.

Journal of Physiology and Pharmacology

|

1995

|

tom 46

|

nr 4

Ograniczanie wyników

7 Journal of Physiology and Pharmacology

5 Piotrowski J.

5 Slomiany A.

5 Slomiany B. L.

2 Konturek S. J.

2 Maczka M.

1 Czajkowski A.

1 Gabryelewicz A.

1 Kaminski K.

1 Kwiecien N.

1 Liu J.

1 Lorens K.

1 Maj A.

1 Obtulowicz W.

1 Oleksy J.

1 Piotrowski E.

1 Sito E.

1 Thor P. J.

1 Torres J.

1 Yotsumoto F.

1 2000

2 1999

1 1995

1 1994

1 1993

1 1992

Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine

Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease

Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans

Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide

Omeprazole fails to suppress up-regulation of gastric mucosal endothelin-converting enzyme-1 by Helicobacter pylori lipopolysaccharide

Endothelin-1, interleukin-4 and nitric oxide synthase modulators of gastric mucosal injury by indomethacin: effect of antiulcer agents

Susceptibility of Helicobacter pylori to antimicrobial agents : effect of ebrotidine and ranitidine